Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02676596 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects
A Phase 1 study of Hyperlipidemia, sponsored by Kowa Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT02676596 is a Phase 1 study of Hyperlipidemia that has completed, run by Kowa Research Institute. The registered enrollment target is 120 participants, below the 404-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02676596, a Phase 1 study of Hyperlipidemia, has completed, sponsored by Kowa Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the safety tolerability, and PK profile of K-312 and its metabolites in healthy Japanese and non-Japanese adults.
Conditions Studied
Interventions
- DRUG K-312 10 mg QD
- DRUG K-312 25 mg QD
- DRUG K-312 50 mg QD
- DRUG K-312 100 mg QD
- DRUG K-312 200 mg QD
Study Locations (1)
California
- - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02676596
The ClinicalTrials.gov registry entry for NCT02676596 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 404-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (70% lower). The listed sponsor is Kowa Research Institute, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperlipidemia appearing as the primary indexed condition, and to 5 interventions - of which K-312 10 mg QD is the first listed.
NCT02676596 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02676596 about?
NCT02676596 is a clinical study titled "Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects". The purpose of this study is to investigate the safety tolerability, and PK profile of K-312 and its metabolites in healthy Japanese and non-Japanese adults.
What is the current status of trial NCT02676596?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2014-04. Estimated completion is 2015-01.
What conditions does trial NCT02676596 study?
This clinical trial studies the following conditions: Hyperlipidemia.
What interventions are being tested in trial NCT02676596?
The interventions under investigation include: K-312 10 mg QD (DRUG), K-312 25 mg QD (DRUG), K-312 50 mg QD (DRUG), K-312 100 mg QD (DRUG), K-312 200 mg QD (DRUG).
Who is sponsoring clinical trial NCT02676596?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02676596 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperlipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Antihyperlipidemic Effects of Oyster Mushrooms
COMPLETED · Phase 1
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease
RECRUITING · NA
-
Inspire HER: Inspiring the Heart and Emotions for Radical Health
RECRUITING · NA
-
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
RECRUITING · Phase 3
-
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.